Commercialisation in the US$1.6 billion nerve repair market is gathering pace for Orthocell Ltd (ASX:OCC, OTC:ORHHF) as the company advances the rollout of its flagship product, Remplir™, in the United States.
Ten surgeries have now been completed using the device, with early adoption progressing in line with Orthocell’s strategy and experience in other markets such as Australia and Singapore, where initial procedures proved pivotal in driving broader clinical uptake and revenue growth.
374Water Inc (NASDAQ:SCWO) revealed its second-quarter revenue jumped to $600,000 from $37,000 a year earlier, driven by biosolids destruction work in Orlando, equipment sales and treatability studies.
CEO Chris Gannon said the quarter was marked by “strong momentum” for its AirSCWO technology, including the start of a biosolids destruction project in Orlando and progress on manufacturing an AS6 system for Orange County Sanitation, expected to be deployed in the second half of 2025.
Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF) announced that its investee Hivello has integrated the Theta Network into its platform, aiming to enhance passive income opportunities for users.
Theta Network becomes the 11th Decentralized Physical Infrastructure Network (DePIN) connected to Hivello’s system, the company said on Tuesday.
New Era Helium Inc (NASDAQ:NEHC) announced it has changed its name to New Era Energy & Digital to reflect a strategic shift toward supplying power and infrastructure for next-generation AI data centers.
The company said the rebrand follows its transformation into a vertically integrated energy supplier focused on digital infrastructure and integrated power assets, including powered land and powered shells.
M2i Global (OTC:MTWO), which develops and executes global supply chains for critical minerals, said on Tuesday it has appointed market analyst and former Chicago Bears linebacker Jon Najarian to its advisory board.
The move comes as M2i pursues its mission to build a US-controlled supply chain for critical minerals, reducing reliance on imports from countries such as China.
Abacus Global Management (NASDAQ:ABL) said on Tuesday it has taken a minority stake in Dynasty Financial Partners, a provider of technology-enabled wealth management solutions for independent financial advisers.
The companies have an existing relationship, with Abacus already part of Dynasty’s network of independent firms using its technology, services, turnkey asset management program, digital lead generation tools, capital solutions and investment bank.
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) shares surged 15% after the company submitted a phase III clinical trial protocol to the US Food and Drug Administration, aiming to broaden the use of its lung imaging agent, XENOVIEW.
Already approved for ventilation imaging, Polarean hopes to expand XENOVIEW’s indication to include quantitative gas-exchange imaging, a technique that measures how efficiently the lungs transfer gas from the air into the bloodstream, a vital sign of lung health.
Cornish Metals Inc (AIM:CUSN, TSX-V:CUSN, OTC:SBWFF) has been awarded an ‘A’ rating in its inaugural ESG evaluation by Digbee, reinforcing both its corporate and project performance.
Digbee’s assessment was conducted by an independent panel of global sustainability experts, and, considered the company’s asset context and management actions.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has submitted a new phase III clinical trial protocol to the US Food and Drug Administration to support an expanded use of its lung imaging agent, XENOVIEW.
The AIM-listed medical imaging company’s contrast agent, already approved for ventilation imaging of the lungs, could gain a broader indication that includes quantitative gas-exchange imaging.
IXICO PLC (LSE:IXI, OTC:PHYOF) has secured two new contracts worth around £1.3 million to provide neuroimaging services for clinical trials in Alzheimer’s disease and Friedreich’s ataxia.
The AIM-listed neuroscience company, known for its artificial intelligence-powered imaging and biomarker analysis, will support a phase I Alzheimer’s trial for a major pharmaceutical firm.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) reported record revenue and profit for its second quarter.
In the three-month period, it sold 25,900 ounces of gold at an average price of US$3,187/oz.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reported strong pre-clinical results for its RECCE® 327 Topical Gel (R327G), showing significant antimicrobial activity and accelerated wound healing in infected burn wounds during in-vivo studies.
The study — part of Recce’s ongoing US Department of Defense (DoD) burn wound program — demonstrated R327G’s effectiveness against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, two antibiotic-resistant bacteria included on the World Health Organization’s list of the most dangerous drug-resistant pathogens.
In its July 29 2025, announcement, AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF) delivered a substantial mineral exploration update covering three major Canadian projects — Cape Ray, Bunker Hill, and Hermitage. With a fully funded program and a strong C$9.2 million treasury, AuMEGA is aggressively expanding its data-driven strategy across Newfoundland’s Cape Ray Shear Zone, Canada’s largest known gold-bearing structure.
Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) has strengthened its cash position with a $2.6 million research and development (R&D) loan facility from Rockford Equity Pty Ltd, providing non-dilutive capital to advance clinical development of its lead intravenous psilocin formulation for Binge Eating Disorder (BED), TRP-8803.
The facility is secured against the company’s projected 2026 financial year (FY) R&D expenditure and will be repaid from future R&D Tax Incentive (RDTI) refunds. Tryptamine can draw down the funding in $500,000 tranches, with interest accruing at 16% per annum on outstanding amounts.
Lithium Universe Ltd (ASX:LU7, OTC:LUVSF) has taken a major step towards advancing sustainable solar panel recycling by acquiring the global rights to Macquarie University’s Jet Electrochemical Silver Extraction (JESE) Technology.
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has provided an update on its share placement announced on July 31, 2025.
PTX, which is developing personalised cancer therapies, previously secured commitments of approximately A$3 million from sophisticated and professional investors. To date, Prescient has received about A$2.5 million, with the second tranche of funding due by August 22, 2025.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) continued to strengthen its global experience with the DurAVR® Transcatheter Heart Valve (THV) in the second quarter of 2025. By June 30, the company had successfully implanted the device in 130 patients since the start of clinical development. This included 49 procedures in the first half of the year and 21 in the June quarter.
The growing body of data demonstrates strong performance of the biomimetic TAVR system across a variety of patient anatomies, including complex cases such as bicuspid valves and valve-in-valve procedures. Notably, the company achieved a world-first “double DurAVR®” implant in a patient requiring replacement in both the mitral and aortic positions.
Imugene Ltd (ASX:IMU, OTC:IUGNF) has extended the closing date of its $15 million Share Purchase Plan (SPP) to Monday, August 25, giving eligible shareholders more time to participate following last week’s positive clinical trial news for its lead cell therapy program, azer-cel.
The company said the decision followed feedback from investors seeking additional time to consider the offer, which opened on July 24 and was originally set to close on August 18, after Imugene reported a strong 79% overall response rate in its Phase 1b trial of the off-the-shelf CAR T therapy. All other terms of the offer remain unchanged.